A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
收藏DataCite Commons2025-10-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002959/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).
提供机构：
Vivli
创建时间：
2018-10-27
